Solnerstotug - Sensei Biotherapeuitcs
Alternative Names: SNA 101; SNS-101 - Sensei Biotherapeutics; SNS-VISTALatest Information Update: 24 Oct 2025
At a glance
- Originator Sensei Biotherapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; VISTA inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 17 Oct 2025 Updated efficacy and adverse events data from a phase I/II trial in Solid tumours released by Sensei Biotherapeutics
- 17 Oct 2025 Sensei plans a phase II trial for Non small cell lung cancer (Second-line therapy or greater, Combination therapy) in 2026
- 17 Oct 2025 Sensei plans a phase II trial for Merckel cell carcinoma in 2026